Lead Sponsor

Galderma R&D

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

•Subject with a clinical diagnosis of plaque psoriasis defined as an IGA score at least 2 (mild) at Screening and Baseline visits
•Subject with a plaque psoriasis total Body Surface Area (BSA) involvement of at least equal to 3% but less than 20% at Screening and Baseline visits
•Subject with a clinical diagnosis of fingernail psoriasis on at least 1 fingernail with a fingernail PGA score from 2 (mild) to 4 (severe) at Screening and Baseline visits

•Subject with guttata, erythrodermic, exfoliative, inverse, pustular or palmo plantar, infected or ulcerated psoriasis or psoriasis involvement \>=20% BSA or an unstable form of psoriasis, defined as at least one flare in the previous month before Screening visit
•Subject with chronic plaque psoriasis who are candidates for systemic therapy at Screening and Baseline visits
•Subject with clinical signs of psoriatic arthritis at Screening and Baseline visits
•Subject with a clinical diagnosis of fingernail psoriasis on at least 1 fingernail with a nail-PGA score from 2 (mild) to 4 (severe) at Screening and Baseline visits.

Related studies

NCT07474792 · Plaque Psoriasis

NCT06857942 · Psoriasis, Overweight or Obesity

NCT06979453 · Plaque Psoriasis

NCT07449234 · Psoriasis

NCT07471048 · Psoriasis

Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis